Similarity analysis of Mobotinib and Moboxetinib

Mobocertinib/Mobocertinib and mobocertinib actually refer to the same targeted anti-cancer drug, and its English generic name is Mobocertinib. The difference between the two Chinese translations comes from the transliteration of the English names in different regions or translation agencies, similar to situations such as "Dasatinib" and "Dasatinib" or "Entrectinib" and "Entrectinib" that are often encountered in medical literature. Mobosetinibis an oral tyrosine kinase inhibitor (TKI), specifically designed to target EGFR exon 20 insertion mutations. Such mutations have low response rates with traditional first- or third-generation EGFR-TKIs, so the emergence of mobosetinib fills this treatment gap.

From the perspective of pharmacological mechanism, mobosetinib interferes with the growth and proliferation of tumor cells by selectively inhibiting the downstream signaling pathways activated by EGFR exon 20 insertion mutations, and especially shows clinical promise in the treatment of non-small cell lung cancer (NSCLC). The FDA approved mobosetinibin 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 20 insertion mutations and whose disease has progressed after prior platinum-containing chemotherapy. The drug is sold under the trade name Exkivity and is developed by Takeda. Regarding the use of Chinese names, "mobosetinib" and "mobosetinib" can be regarded as reflections of different transliteration habits, and there is no difference in the actual drug ingredients, indications and efficacy.

Currently, the drug has not been officially launched in mainland China, so its Chinese name has not been uniformly approved by the State Food and Drug Administration, which is also the main reason for translation differences. When patients inquire about relevant information, whether they use "mobocertinib" or "mobocertinib", they should ensure that the English name is Mobocertinib to avoid confusion or misinformation.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib